NCT00083421已完成2 期
Effects of ONO-2506PO in Patients With Alzheimer's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 647
- 试验地点
- 169
- 主要终点
- Cognitive Function Scale
研究概览
简要总结
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
- •Standardized MMSE Score of 13 to 24 points (inclusive)
- •Modified Hachinski score equal or less than 4
排除标准
- •Serious systemic disease that may preclude survival to study completion
- •Other illnesses that may include dementive features
结局指标
主要结局
Cognitive Function Scale
Global Function Scale
次要结局
- ADL Scale
- Psychiatric Symptom Scale
研究者
研究点 (169)
Loading locations...
相似试验
已完成
2 期
Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in JapanParkinson's DiseaseNCT00212693Ono Pharmaceutical Co. Ltd165
终止
2 期
A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic StrokeCerebrovascular AccidentNCT00046761Ono Pharma USA Inc1,320
已完成
2 期
Study of ONO-2506 in Patients With Acute Ischemic StrokeStrokeNCT00229177Ono Pharmaceutical Co. Ltd757
已完成
2 期
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)NCT00403104Ono Pharmaceutical Co. Ltd420
Unknown
不适用
APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's DiseaseAlzheimer DiseaseNCT04994847Banner Health300